<- Go Home
Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Market Cap
DKK 14.1B
Volume
367.1K
Cash and Equivalents
DKK 1.7B
EBITDA
DKK 1.7B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
DKK 3.1B
Profit Margin
49.20%
52 Week High
DKK 244.80
52 Week Low
DKK 150.85
Dividend
N/A
Price / Book Value
1.12
Price / Earnings
10.46
Price / Tangible Book Value
2.09
Enterprise Value
DKK 10.9B
Enterprise Value / EBITDA
6.49
Operating Income
DKK 1.0B
Return on Equity
11.33%
Return on Assets
4.41
Cash and Short Term Investments
DKK 3.3B
Debt
DKK 130.9M
Equity
DKK 12.9B
Revenue
DKK 6.2B
Unlevered FCF
-DKK 917.8M
Sector
Biotechnology
Category
N/A